Acambis, sanofi-aventis deal

sanofi-aventis will acquire vaccine company Acambis for 190p per share or about £276 million ($553 million) in cash. The price is a 64% premium to Acambis’ close of

Read the full 289 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE